House AER bill
This article was originally published in The Tan Sheet
Rep. Chris Cannon (R-Utah) introduces a House version of legislation mandating adverse event reporting for dietary supplements and OTC drugs Sept. 25. The bill goes to the House Committee on Energy & Commerce, where a hearing is expected shortly after the House reconvenes in November. The "Dietary Supplement & Nonprescription Drug Consumer Protection Act" (HR 6168) requires manufacturers, packers or distributors of OTC drugs or dietary supplements "whose name appears on the label" to report any serious adverse events to FDA, the legislation states. The provisions of the bill would take effect one year after enactment. Sen. Orrin Hatch (R-Utah) believes the introduction of the House supplement AER bill "will boost [the legislation's] prospects for enactment this Congress," according to a staffer. It is likely the Senate will vote on the related legislation (S 3546) in early October, according to several supplement industry trade groups (1"The Tan Sheet," Sept. 18, 2006, p. 6)...
You may also be interested in...
Congress was poised late last week to pass a bill requiring mandatory adverse event reporting for dietary supplements and nonprescription drugs
The Senate likely will vote on the "Dietary Supplement & Nonprescription Drug Consumer Protection Act" (S 3546) before they adjourn in early October, according to several supplement industry trade groups
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.